Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for AZL10001

Result Summary for AZL10001

Result Summary

Protocol ID:	AZL10001
Clinical Study ID:	AZL10001
Official Title:	An Evaluation of the Bioequivalence of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) Compared to ZIAGEN (abacavir) 300mg tablet, EPIVIR (lamivudine) 150mg tablet, and RETROVIR (zidovudine) 300mg tablet Administered Concurrently and the Effect of Food on Absorption i ...
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus I
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	trizivir;trizivir
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Yuen GJ, Lou Y, Thompson NF, Otto VR, Allsup TL, Mahony WB, Hutman HW Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol. 2001 Mar;41(3):277-88.